Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The development marks a significant step toward integrating artificial intelligence into pharmaceutical production, potentially transforming how sterile injectables are manufactured.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI platform across sterile manufacturing operations, including electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. According to the company, the integrated platform combines PDAOAI with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services.
Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. This announcement comes as the company continues to leverage its AI-enabled PDAOAI platform, which supports research, biomarker discovery and regulatory processes through advanced data analysis and knowledge integration. The platform is part of CEO Dr. Vuong Trieu’s portfolio of over 500 patent applications and 75 issued patents.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens its position in oncology and rare disease therapeutics.
For more details, the full press release is available at https://nnw.fm/j1n43. Additional updates and information about Oncotelic can be found in the company’s newsroom at https://nnw.fm/OTLC.
